Publicaciones en colaboración con investigadores/as de Hospital Universitario de la Princesa (13)

2023

  1. Do Elderly Patients with Heart Failure and Reduced Ejection Fraction Benefit from Pharmacological Strategies for Prevention of Arrhythmic Events?

    Cardiology, Vol. 148, Núm. 3, pp. 195-206

  2. Do Women Physicians Accept and Follow Heart Failure Guidelines More Than Men?

    Current Heart Failure Reports, Vol. 20, Núm. 3, pp. 151-156

  3. Opinion on the 2021 ESC guidelines on heart failure: a cross-sectional survey of 387 doctors

    REC: CardioClinics, Vol. 58, Núm. 1, pp. 7-15

2022

  1. Frailty and prognosis of older patients with chronic heart failure

    Revista Espanola de Cardiologia, Vol. 75, Núm. 12, pp. 1011-1019

  2. Impact of blood pressure on management and prognosis of patients treated with sacubitril/valsartan

    REC: CardioClinics, Vol. 57, Núm. 2, pp. 116-122

2021

  1. Initiation and titration of sacubitril/valsartan in different types of centers

    REC: CardioClinics, Vol. 56, Núm. 2, pp. 92-97

2020

  1. Left Ventricular Ejection Fraction Recovery in Patients with Heart Failure and Reduced Ejection Fraction Treated with Sacubitril/Valsartan

    Cardiology (Switzerland), Vol. 145, Núm. 5, pp. 275-282

  2. Sacubitril/Valsartan is useful and safe in elderly people with heart failure and reduced ejection fraction. Data from a real-word cohort

    Revista Espanola de Geriatria y Gerontologia, Vol. 55, Núm. 2, pp. 65-69

  3. Selection of the best of 2019 in geriatric cardiology

    REC: CardioClinics, Vol. 55, pp. 3-9

2019

  1. Safety of sacubitril/valsartan initiated during hospitalization: data from a non-selected cohort

    ESC Heart Failure, Vol. 6, Núm. 6, pp. 1161-1166

  2. Selection of the best of 2018 in geriatric cardiology

    REC: CardioClinics, Vol. 54, pp. 10-15

  3. Sex Influence on the Efficacy and Safety of Sacubitril/Valsartan

    Cardiology (Switzerland), Vol. 142, Núm. 2, pp. 73-78

2018

  1. Clinical Profile of a Nonselected Population Treated With Sacubitril/Valsartan Is Different From PARADIGM-HF Trial

    Journal of cardiovascular pharmacology, Vol. 72, Núm. 2, pp. 112-116